Duchenne muscular dystrophy (DMD) is a rare X-linked recessive disorder that occurs in around one in 5,000 male births. The prevalence of DMD is expected to rise due to improved standards of care and implementation of guidelines, leading to longer survival. Specialist genetic confirmation of a DMD diagnosis is typically followed by access to specialist care and treatment: the exact DMD-causing mutation should be identified because it can influence prognosis and identify patients eligible for treatment. Since the majority of patients has a deletion or duplication of one or more exons (~70 %), generally multiplex ligation-dependent probe amplification suffices to identify the mutation. Exon sequencing is performed to pick up small mutations (~30 %). Greater awareness of DMD is needed among healthcare professionals to enable earlier diagnosis, which would facilitate family planning, as well as patient care and treatment. In DMD patients who are still able to walk, the 6-minute walk test (6MWT) has been shown to be a valid measure of physical functioning and a predictor of disease progression, with high inter-test reliability. In a study of the natural history of DMD, change in 6MWT of around 30 metres has been indicated to be clinically relevant and clinically meaningful. DMD patients responded to treatment as shown by the improvement in the 6MWT score in the large multinational trial of the nonsense mutation readthrough agent, ataluren (Translarna™) 40 mg/kg/day, where treatment was associated with a 31.3 metres improvement on the 6MWT distance, after 48 weeks, compared with placebo. The Translational Research in Europe-Assessment & Treatment of Neuromuscular Diseases (TREAT-NMD) network was launched to provide an infrastructure to accelerate research and therapy development, increasing collaboration, improving patient care and helping to support 'clinical trial readiness'. As such, the TREAT-NMD registry network is well placed to support further understanding of DMD and the impact of therapies that may be used over the long term, permitting a host of research questions to be explored.
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The Dubowitz Neuromuscular Centre, University College London, London Duchenne muscular dystrophy (DMD) is a rare X-linked recessive disorder mutation in the DMD gene, Xp21. It is a progressive disease that is characterised by lack of dystrophin, which leads to severe myofibre degeneration. This, in turn, results in a relentless decline in physical functioning with subsequent respiratory and cardiac failure, leading to early death. One estimate of cost of DMD from a recent study carried out by Translational Research in Europe-Assessment & Treatment of Neuromuscular Diseases (TREAT-NMD) and GSK using TREAT-NMD registries in four countries found the yearly society cost to be in the region of $80,120-120,910 (€70,765-106,792) per patient and the corresponding household burden between $58,440-71,900 (€51,616-63,505). 1 However, due to difficulties in capturing end-of-life costs for DMD patients, these may be conservative estimates.
Recent estimates put the birth incidence in males of DMD at approximately 1:5,000. 2, 3 The natural history of DMD is becoming better understood and care guidelines are available that help physicians provide optimal care. The global prevalence is expected to rise due to improved survival and standards of care. These improvements are the result of better understanding of DMD complications, implementation of guidelines and enhanced care practices, for example, the introduction of non-invasive positive pressure ventilation (NIPPV) for respiratory complications. 4 Kaplan-Meier survival analyses from the Newcastle Muscle Centre, International Centre for Life, Newcastle upon Tyne, UK showed significant decade on decade improvement in survival: the mean age of death in the 1960s was 14.4 years, whereas for those who had received NIPPV since 1990, it was 25.3 years. 5 Another important advance is the use of glucocorticoid therapy to improve muscle strength and function. 6, 7 In an assessment of 360 boys aged 3-15 years who were treated with daily or intermittent (10 days on/10 days off) prednisolone for a mean duration of treatment of 4 years, the median loss of ambulation was 12 years in the intermittent treatment group and 14.5 years in the daily treatment group. 8 Despite these advances in standards of care and the emerging understanding of DMD natural history, progressive muscle loss in DMD cannot currently be avoided, and loss of ambulation in patients with DMD is eventually followed by loss of upper limb function, loss of self-feeding and respiratory insufficiency.
Restoring dystrophin expression remains the ultimate goal for treatment so that the time to these events could be delayed as much as possible. n
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Dystrophin acts as a shock absorber by connecting cytoskeletal actin within muscle fibres to the extracellular matrix surrounding muscle fibres.
In DMD, dystrophin is prematurely truncated and non-functional. This contrasts to Becker Muscular Dystrophy (BMD), which is typically caused by in-frame dystrophin deletions that allow the production of an internally deleted but partially functional dystrophin. BMD occurs in approximately one in 20,000 men.
Deletions or duplications of one or more exons are the most common mutation in DMD accounting for over two-thirds of DMD cases. 9 Small mutations have also been described, including nonsense mutations, small insertions, deletions, inversions and splice site mutations. Other rarer mutations found include intronic mutations and pseudoexon activation, translocations and missense mutations.
A deletion or duplication disrupts the reading frame for DMD, i.e. the number of nucleotides missing (or being duplicated) from the exons is not divisible by three, resulting in a shift in the translational reading frame, and aberrant amino acids used for protein formation and generally a premature truncation signal. Similarly, small insertions/deletions can also disrupt the reading frame. For splice site mutations the exon is not recognised and excluded from messenger RNA (mRNA), which (like deletions) can lead to a reading frame shift if the number of nucleotides in that exon is not divisible by three. In the case of nonsense mutations, which affect approximately one in 27,000 male births (~13% of mutations), the reading frame is not affected, but a codon for an amino acid is changed into a stop codon, causing the dystrophin protein to truncate prematurely and being non-functional.
The frequency of the various mutations in males with DMD were estimated using data from the Leiden Open (source) Variation Database (LOVD; n=4,770) 9 and the TREAT-NMD Global database (n=7,172). 10 Deletions were the most common mutations identified and were present in 65 % of patients in the LOVD database and 69 % in the TREAT-NMD registry. The location and extent of the in-frame mutation was found to impact on the disease severity of Becker patents, as shown in Figure 1 . 9, 11 When a deletion disrupts the crucial actin-binding domains and/or the binding domain for beta-dystroglycan (which connects to the extracellular matrix) the resulting dystrophin is not functional and patients have a DMD phenotype. Also, when there is a large deletion in the central domain (>36 exons), a DMD phenotype will generally result. Frame-shifting dystrophin mutations would be expected to result in DMD, but mutations prior to exon 8 can present as BMD instead as there are alternative start sites in exon 8, and this can compensate for the earlier mutation. Furthermore, frame-shifting mutations flanking exon 44 generally have a more mild disease course than typical DMD.
Central rod domain H1 S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 H3 S20 S21 S22 S23 S24 H4 H2 Actin binding domain   Exon   nNOS   nNOS  Dystroglycan BD   WW EF EF  ZZ  CC CC   SBD DBD   1  3  5  7  9  1 1 13 15 17 19  2 1  23 25 27 29 31 33  35 37 39  41 43 45 47 49  51 53  55 57 59 61  63  65  67  69 71 73 75  77 79  78  76  74  72  70  68  66  64  62  60  58  56  54  52  50  48  46  44  42  40  38  36  34  32  30  28  26  24  22  20  18  16  14  12  10  8  6 Early diagnosis is crucial for DMD to allow informed family planning and also appropriate planning for the patient's care and treatment. 12, 13 Medical examination should be carried out by a neuromuscular disease specialist and should be considered when: the child is male, muscle function is impaired (as revealed by frequent falls, Gower's sign, etc.), there is delayed speech (which may be more pronounced than muscle impairment), serum creatine kinase levels are elevated (10-100 times normal) accompanied by high aspartate transaminase and alanine transaminase levels. 12, 13 Genetic confirmation, requiring full complementary DNA (cDNA) sequencing in patients in whom no deletion or duplication can be found, is essential to allow for carrier testing and to find out whether the patient is eligible for mutation-specific approaches to DMD management.
Cysteine rich/C-terminal domains
Several methods are required for genetic confirmation of DMD. Multiplex polymerase chain reaction (PCR) generally uses two sets of primers to detect the presence or absence of a selected number of exons.
The method is inexpensive and straightforward but for many patients the exact extent of the deletion is not known, while this is crucial to assess if the reading frame is disrupted or maintained. Also, this method does not detect duplications and cannot be used for carrier detection. [15] [16] [17] [18] In the 6MWT, the distance covered walking fast as possible on flat ground for 6 minutes is recorded. A 25 metre course is marked by two cones at each end, around which the patient will turn. The patient can stop if tired, but not sit, and resume walking as soon as possible. Distances are marked at each lap and every minute.
The 6MWT has been shown to be feasible, safe and reproducible as an outcome measure for DMD natural history and therapeutic trials. [15] [16] [17] [18] A longitudinal study that was conducted to assess changes over 24 months in ambulant boys with DMD showed that there was an average overall decline of -22.7 (standard deviation [SD] 81.0) in the first year on the 6MWT and -64.7 (SD 123.1) in the second year. 19 More recently, a 3-year study following up these 24-month data showed that age was an important determinant to prognosis in DMD, with children older than 7 years of age showing a much more rapid deterioration on the 6MWT than children below the age of 7 years. 20 This follow-up study also demonstrated that baseline walking and functional ability, as measured by 6MWT performance, is also a major factor in determining the rate of DMD patient decline. These findings are consistent with other longitudinal natural history observations in DMD. 15 EuropEan nEurological rEviEw A decline of 30 metres on 6MWT has been demonstrated to be clinically meaningful and predictive of loss of ambulation and correlated with a clinically meaningful change in QoL. 21 The 6MWT has been validated against other measures in DMD, including measures of muscle strength (knee extensors), 22 gross motor skills (the functional scale, North Star Ambulatory Assessment [NSAA]), 18, 19 endurance (continuous step activity) 16 and timed items (10 metres and Gowers). 19 The NSAA is a clinical evaluation tool designed specifically for children with DMD. The NSAA protocol sets out a standard timed function test for clinicians to assess the ability of the child to perform 17 activities, including standing, head-raising, hopping and running. The NSAA is a practical and reliable test that can be completed in 10 minutes 23,24 and, with adequate training in place, can be used in a multicentric setting for DMD clinical research and trials. 24, 25 As previously stated, outcome measures in DMD should be sensitive to change and responsive to treatment. Based on two statistical distribution methods, the minimal clinically important differences (MCIDs) in DMD for the 6MWT have been reported to be 28.5 metres and 31.7 metres. 22 In the phase IIb trial (sponsored by PTC Therapeutics, Inc.) of the nonsense mutation readthrough agent, ataluren (Translarna™), nonsense mutationmediated DMD patients receiving ataluren (40 mg/kg/day) showed a clinically meaningful difference (approximately 30 metres) in the change in their 6MWT results compared with the placebo arm. Treatment resulted in a mean decline from baseline in 6MWT of 12.9 metres compared with 44.1 metres for patients receiving placebo over 48 weeks (p=0.0561; see Figure 2 ), suggesting that the 6MWT measure is responsive to treatment in ambulatory DMD patients. 26 The changes in 6MWT have also been correlated with timed function tests in DMD, such as the 10 metre walk/run. 22 In addition, 6MWT changes are associated with changes in other measures reflecting other aspects of daily activities, e.g. the functional scale, NSAA. 19, 27 The 6MWT has also been correlated with person-reported outcomes (Paediatric Outcomes Data Collection Instrument [PODCI). 19 It is also important to develop outcome measures for use in younger children, although this can be challenging. In a study by De Sanctis et al. 28 patients across 35 countries, and more will be included in the future as other countries join.
The TREAT-NMD network provides an invaluable research tool for trial readiness (feasibility and recruitment), and to assess standards of care (CARE-NMD), biomarker discovery and validation (BIO-NMD) as well as investigating burden of illness and the natural history and outcomes.
The wealth of data that can be obtained is illustrated in Figure 3 , which shows the patient numbers for the five most common exon skips across different countries in the TREAT-NMD network in 2010. Selecting a particular exon as an inclusion parameter immediately narrows the cohort, and international collaboration is essential for trial feasibility and recruitment, i.e. to gain sufficient patient numbers to facilitate research.
There are numerous examples of the TREAT-NMD registry being used to address research questions for DMD. As an example, to explore the changing natural history of DMD, registry data for each country in TREAT-NMD were transferred to a central database (n=6,787). 10 Only patients with a fully confirmed DMD mutation were included in the final analysis and the data were subject to data cleaning and plausibility checks (H Lochmüller et al., manuscript in preparation). The data showed variation in steroid uptake across different countries, revealing that care standards are being not applied equally worldwide. When the effects of this on outcomes are examined, a negative correlation can be discerned between steroid use and lack of ambulation at age 12-17 years (see Figure 4 ). Steroid users were five times more likely to walk at age 12-17 years than those who did not use steroids.
Similarly, an inverse correlation was shown between steroid use and the requirement for scoliosis surgery, whereby those who used steroids were five times less likely to require scoliosis surgery than non-steroid users. No significant effect of steroids on the onset of cardiomyopathy was apparent however.
Expansion is planned for TREAT-NMD registries to assist recruitment for industry-sponsored trials, with new sites and diseases to be included in the Care and Trial Site Registry. In addition, the action plan for 2014 to 2016 includes improved visibility for centres of excellence, data curation to avoid duplication of data entry and collaboration with research networks, patient organisations and with industry to provide feedback to patient organisations and to facilitate post-marketing studies. Regarding the collaboration with industry, post-marketing studies are needed to understand the safety signals and long-term treatment outcomes of new therapies, and may become a requirement by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA). To help fulfil this requirement and to potentially address other long-term research questions, further investment is focussing on setting up a system to allow standardised and more complete data capture (i.e. auditable data, similar to clinical trials) in anticipation of supporting these future needs. n
